Acomhal Research
Roanoke, US · Virginia corporation
Acomhal Research develops a peptide drug designed to target and eliminate cancer stem cells, preventing tumor recurrence and metastasis across multiple cancer types including glioblastoma, breast cancer, and others. The company operates in the biotech sector, focusing on novel therapeutics for drug-resistant cancers.
Founders & leadership
SL
Samy LamouilleCo-founder & Chief Executive Officer
RG
Robert GourdieCo-founder
Board
CR
Craig RameyBoard director
Reported raises · per SEC filings
Form D private placements$300K disclosed across 1 round · 2021
▶$300KraisedApr 2021 · 6 investors · BiotechnologyRule 506(b)
▶$300KraisedApr 2021 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Craig RameyDirector
- Samy LamouilleExecutive Officer, Director
- Robert GourdieExecutive Officer, Director
- Offering amount
- $500K
- Amount sold
- $300K
- Minimum investment
- $10K
- Proceeds to insiders
- $19K
- First sale
- Apr 2021
- Incorporated
- Corporation, Virginia
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Acomhal Research do?
- Acomhal Research develops a peptide drug designed to target and eliminate cancer stem cells, preventing tumor recurrence and metastasis across multiple cancer types including glioblastoma, breast cancer, and others. The company operates in the biotech sector, focusing on novel therapeutics for drug-resistant cancers.
- How much funding has Acomhal Research raised?
- Acomhal Research has disclosed $300K raised across 1 round.
- Where is Acomhal Research headquartered?
- Acomhal Research is headquartered in Roanoke, US.